MiR-9 is upregulated in TNBC in comparison with the luminal and HER2-enriched breast cancer subtypes [199] and stimulates cell motility and invasion ability by targeting E-cadherin, activating the β-catenin pathway and enhancing VEGF levels [195]. This evidence concerns the gene CDH1 and breast cancer.